Abstract
An increase of angiogenesis has been shown in idiopatic myelofibrosis with myeloid metaplasia (MMM) by microvessel density count method but evaluation of circulating angiogenic factors is still incomplete. In 31 patients affected by MMM and in 12 healthy subjects we evaluated the serum levels of VEGF (vascular endothelial growth factor) and correlated VEGF with clinical and laboratory features of disease. We found that MMM patients had circulating VEGF concentrations much higher than controls (median 1208 ng/ml vs 138 ng/ml, P < 0.0001). No correlation was found between VEGF and Hb, WBC, PLT, LDH, creatinine, bone marrow cellularity, fibrosis, splenomegaly, hepatomegaly, and therapy. However, in the subgroup of patients with a normal or low VEGF concentration, a direct correlation between VEGF and platelet count (r = 0.90, P = 0.002) was detected. Moreover, patients with a platelet count <300 × 109/l had VEGF serum levels lower than patients with a higher PLT count (median VEGF 864 vs 1557 pg/ml, P = 0.001). In six patients and in eight controls we also had the opportunity to measure VEGF in the plasma and we calculated that VEGF concentration was much higher in platelet-rich than in platelet-poor plasma and that platetets of MMM patients contained four times more VEGF than those of healthy controls. These results indicate that VEGF is overproduced in MMM, thus confirming an increased angiogenic activity. Platelets are probably a major source of VEGF in MMM but not the only one.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ferrara N, Davis-Smyth T . Biology of vascular endothelial growth factor Endocr Rev 1997 18: 4–25
Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmè D, Gastl G . Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease Cancer 1999 85: 178–187
Ratajczak MZ, Ratajczak J, Machalinski B, Majka M, Marlicz W, Carter A, Pietrzkowski Z, Gewirtz AM . Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (P1GF) in regulating human haemopoietic cell growth Br J Haematol 1998 103: 969–979
Vacca A, Ribatti D, Presta M, Monischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F . Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 1999 93: 3064–3073
Weidner N, Folkman J . Tumor vascularity as a prognostic factor in cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Important Advances in Oncology Lippincott-Raven: Philadelphia 1996 167–190
Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M . Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia Blood 1999 94: 3717–3721
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner S, Harris AL, Dirix LY . Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation Eur J Cancer 1996 32A: 2474–2484
Risau W . Mechanisms of angiogenesis Nature 1997 386: 671–674
Kim J . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vitro Nature 1993 362: 841–844
Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT . Elevated levels of the angiogenic cytokines basic fibroblastic growth factor and vascular endothelia growth factor in sera of cancer patients Br J Cancer 1997 76: 238–243
Salven P, Teerenhovi L, Joensuu H . A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma Blood 1997 90: 3167–3172
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J . Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 1997 150: 815–821
Aguayo A, Kantarjian H, Estey E, Cortes J, Beran M, O'Brien S, Keating M, Freireich E, Thomas D, Rogers A, Albitar M . Plasma levels of VEGF and bFGF in various leukemias and their correlation with angiogenesis Blood 1999 94 (Suppl. 1): 503a, (Abstr. 2252)
Bellamy WT, Richter L, Frutiger Y, Sirjani D, Glinsmann-Gibson B, Grogan TM, List AF . Vascular endothelial growth factor (VEGF) is an autocrine promoter of ALIP and leukemia progenitor formation in myelodysplastic syndromes (MDS) Blood 1999 94 (Suppl. 1): 389a, (Abstr. 1727)
Mattern J, Koomagi R, Volm M . Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma Br J Cancer 1996 73: 931–934
Thiele J, Rompcik V, Wagner S, Fisher R . Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow Br J Haematol 1992 80: 227–234
Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J . Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity Am J Pathol 2000 157: 15–19
Tefferi A . Myelofibrosis with myeloid metaplasia N Engl J Med 2000 342: 1255–1265
Mesa RA, Hanson CA, Rajkumar SV, Schroeder GS, Tefferi A . Evaluation and clinical correlations of microvessel density in myelofibrosis with myeloid metaplasia Blood 2000 96: 3374–3380
Dalley A, Smith JM, Reilly JT, MacNeil S . Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calodulin in fibroblast proliferation Br J Haematol 1996 93: 856–862
Le Bousse-Kerdiles M-C, Chevillard S, Charpentier A, Romquin N, Clay D, Smadja-Joffe F, Praloran V, Dupriez B, Demory J-L, Jasmin C, Martirè M-C . Differential expression of transforming growth factor-β, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia Blood 1996 88: 4534–4546
Martirè M-C, Le Bousse-Kerdiles M-C, Romquin N, Chevillard S, Praloran V, Demory J-L, Dupriez B . Elevated levels of basic fibroblast grwoth factor in megakaryocyts and platelets from patients with idiopathic myeofibrosis Br J Haematol 1997 97: 441–448
Salven P, Oprana A, Joensuu H . Leukocyte and platelets of patients with cancer contain high levels of vascular endothelial growth factor Clin Cancer Res 1999 5: 487–491
Wynendaele W, Derua R, Hoylaerts MF, Pawinski A, Waelkens E, de Bruijn EA, Paridaens R, Merlevede W, van Oosterom AT . Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999 10: 965–971
Goldberg MA, Schneider TJ . Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin J Biol Chem 1994 269: 4355–4361
Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ . Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology Br J Cancer 1998 76: 956–964
Salgado R, Vermeulen PB, Benoy I, Weytjiens R, Huget P, Van Mark E, Dirix LY . Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients Br J Cancer 1999 80: 892–897
Verheulen HMW, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxtermann HJ, Pinedo HM . Platelet: transporter of vascular endothelial growth factor Clin Cancer Res 1997 3: 2187–2190
Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y . Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effet of VEGF on apoptotic cell death caused by ionizing radiation Cancer Res 1995 55: 5687–5692
Mohle R, Green D, Moore MA, Nachman RL, Rafii S . Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets Proc Nat Acad Sci USA 1997 94: 663–668
Huang Y-Q, Li J-J, Hu L, Karpatkin S . Thrombin induces vascular endothelial cell growth factor (VEGF) in human tumor cells and fibroblasts Blood 1999 94 (Suppl. 1): 12a, (Abstr. 40)
Ziegler BL, Valtieri M, Almeida Porada G, De Maria R, Muller R, Masella B, Gabbianelli M, Casella I, Pelosi E, Bock T, Zanjani ED, Peschle C . KDR receptor: a key marker defining hematopoietic stem cells Science 1999 285: 1553–1558
Barosi G . Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines J Clin Oncol 1999 17: 2954–2970
Thomas DA, Aguayo A, Giles FJ, Albitar M, O'Brien S, Cortes J, Faderl S, Bivins C, Zeldis J, Keating MJ, Barlogie B, Kantarjian MJ . Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF) Blood 1999 94 (Suppl. 1): 702a, (Abstr. 3102)
Acknowledgements
This study was supported in part by FON.CA.NE.SA. (Fondazione Catanese per lo Studio e la Cura delle Malattie Neoplastiche del Sangue).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raimondo, F., Azzaro, M., Palumbo, G. et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 15, 976–980 (2001). https://doi.org/10.1038/sj.leu.2402124
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402124
Keywords
This article is cited by
-
Mathematical Modeling and Analysis of CD200–CD200R in Cancer Treatment
Bulletin of Mathematical Biology (2022)
-
Inflammatory mediators reduce surface PrPc on human BMVEC resulting in decreased barrier integrity
Laboratory Investigation (2018)
-
The role of the extracellular matrix in primary myelofibrosis
Blood Cancer Journal (2017)
-
Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations
Annals of Hematology (2017)
-
Decreased TGF-β1 and VEGF Release in Cystic Fibrosis Platelets: Further Evidence for Platelet Defects in Cystic Fibrosis
Lung (2016)